Background {#Sec1}
==========

Polypharmacy {#Sec2}
------------

The care of patients with multiple chronic diseases entails many challenges, in particular related to higher than average coordination and medication complexity. In an European study Fialova et al. found that 51 % of participating patients take more than six prescribed medications per day \[[@CR1]\].

Overall, 20 % of GPs' patients older than 65 years receive 60 % of all prescribed drugs \[[@CR2]\]. In fact, polypharmacy comes along with frequently undesirable consequences, such as increased risk of inappropriate drug use, under-use of effective treatments, medication errors, drug interactions, poor patient compliance, and adverse drug reactions \[[@CR3]\]. Regarding this, medication management provided by pharmacists may overcome these challenges \[[@CR4], [@CR5]\].

Current interventions and MTM approaches {#Sec3}
----------------------------------------

Pharmaceutical practice worldwide is currently developing towards patient care. Pharmaceutical care has been promoted by Hepler and Strand of the University of Florida in 1990 and has been redefined by the PCNE in 2013/2014 \[[@CR6], [@CR7]\]. According to the PCNE definition, pharmaceutical care covers numerous activities to "optimize medicines use and improve health outcomes". Certain care aspects, like enhanced patient education have been well described and studied: Jalal et al. found patient education, provided by pharmacists beneficial in cardiovascular diseases \[[@CR8]\], Schmiedel et al. recently found that patient education can reduce the risk to acquire diabetes \[[@CR9]\]. Several studies could support the efficacy of patient counseling on drug-adherence \[[@CR10]\] or patient skills in handling drug-devices \[[@CR11]--[@CR13]\].

The WHO and FIP have promoted a patient centered approach by publishing a handbook in 2006 \[[@CR14]\]. Medication Review (MR) and Medication Therapy Management (MTM) are evolving as the most prominent services in pharmaceutical care and have a strong potential to provide a large benefit for patients and society. A comprehensive MTM can only be performed in an interprofessional setting \[[@CR15]\]. Several international studies have explored the effects of a MTM on the quality of therapy and costs \[[@CR16], [@CR10], [@CR17], [@CR18]\]. A systematic review of Nkansah et al. found that the available trials are varying in study design and endpoints and hardly can be compared to services of other health care providers. Hence further studies on Medication Management are desired \[[@CR19]\].

The impact of pharmaceutical services widely differs among societies with the setting of the national health care system. Differences in education and collaboration as well as structures and barriers between professions lead to a variety of possible outcomes. For Germany the data supporting a MTM is still deficient.

Novel aspects of the interprofessional medication therapy management approach {#Sec4}
-----------------------------------------------------------------------------

Most studies on MTM are examining certain effects of the intervention of the participating pharmacists and are evaluated by themselves. Pharmaceutical aspects, like a change in drug-adherence or a reduction in drug related problems are assessed \[[@CR20]--[@CR22]\].

Interventions can only reach the patient if they are approved by the decision maker, the general practitioner (GP) or primary care provider (PCP). A consensus between all health care providers is likely to support the therapy. The WestGem-study has a pronounced focus on interprofessional cooperation and collaboration. It might be one of the first Medication Therapy Management studies combining three participating health care professions, consisting of physicians, pharmacists and home-care specialists. The interprofessional approach combines case management routines of the home-care specialists at the patient-site with information gained during the advanced Medication Review by specialised and clinical experienced study pharmacists.

The development of the approach was based on the Medical Research Council (MRC) guideline for the development and evaluation of randomized controlled trials \[[@CR23], [@CR24]\]. It was piloted with a group of seven GPs, two pharmacists and two home-care specialists.

Study aim and objectives {#Sec5}
------------------------

The aim of this randomized controlled trial is to evaluate the application of an interprofessional collaborative Medication Therapy Management approach in multimorbid patients, receiving multiple systemic available drugs. The evaluation refers to the extent of improvement in the quality of drug therapy through examination of drug related problems (DRPs) or drug related events and suggestions on optimizing drug use to reach therapeutic goals. Several tools are used to assess the patients' drug therapy and home-care needs.

Part of the complex intervention might be the removal of inappropriately prescribed medication, disclosure of drug related problems and prescribing cascades, assessing drug-drug interactions, determination of therapeutic goals, evaluation of pain management, the assessment of chief complaints and quality of life and a reflection of costs and cost-effectiveness of this complex intervention under terms of routine care.

Methods {#Sec6}
=======

Primary objective {#Sec7}
-----------------

The primary objective of this study is to determine whether the complex intervention would change the quality of medication therapy determined by the MAI (medication appropriateness index) \[[@CR25], [@CR26]\] in comparison to standard care. The intervention focuses on multimorbid patients receiving polypharmacy. It is done supplementary to standard care.

Secondary objectives {#Sec8}
--------------------

Secondary outcomes include changes in the number of drug related problems, classified according to PCNE version 6.2, medication complexity, measured by the MRCI \[[@CR27]\], changes in adherence (measured by the Morisky-score \[[@CR18]\]), changes in health-status and function, quality of life, direct and indirect costs, and the incremental cost-effectiveness ratio.

Setting {#Sec9}
-------

The study is conducted in a community and outpatient primary care setting in two model regions in North Rhine-Westphalia, located in Western Germany. We have chosen regions with different network structures, which enables us to measure performance and outcomes of the interprofessional medication therapy management approach while taking setting specific influence factors into account.

Outpatient health care in *region A* is organised as a network including GPs (n ≈ 15) and medical specialists (n ≈ 18). Outpatient health care in *region B* does not present in any network structure (number of available GPs in this area is ≈ 55). Local GPs of the *model regions* are contacted by an informative letter, briefly explaining details of the planned intervention and essential study tasks. After written confirmation of participation in the study by interested GPs, the project assistants visit the participating GPs personally to explain the study design, provide study instruction and gain the GPs' agreement to participate. In this context, a monetary incentive is provided to positively influence participation and cooperation \[[@CR28]--[@CR30]\]. Considering the experience of previous research for studies with relatively high workload for documentation, patient recruitment and study intervention, we expect a response-rate of 6 − 10 % \[[@CR31], [@CR32]\] for region B. Furthermore we expect, that the existing network structure in region A will generate a higher response rate.

Study design {#Sec10}
------------

The study is designed as a cluster-randomized controlled trial, incorporating qualitative analysis. The qualitative analyses have been used during intervention development and piloting. Further qualitative methods will be applied to perform a process evaluation of the randomized trial and to assess the acceptance of the interprofessional Medication Therapy Management approach \[[@CR33]\]. The study design is developed in line with the CONSORT statement extension to cluster RCT \[[@CR34], [@CR35]\]. The cluster design is chosen to avoid spillover effects across patients of the control and intervention groups. To ensure the feasibility and a high acceptance of the methodical cornerstones of the study, its essential aspects were piloted. Thereby the patients recruiting process, randomization routines, the applied documentation forms and data collection procedures are examined.

Participating GPs are allocated to one of three study arms by undertaking a cluster randomization on the level of the primary care units following a Stepped Wedge Design \[[@CR36]\]. In this sense all GPs are initially assigned to the control group. After a 6 month observation period, general practitioners are randomly allocated to one of the three groups and the interprofessional Medication Therapy Management approach is implemented sequentially per each group with a lag of 3 months (see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Design of the WestGem-study. This figure shows design and timeframe of the WestGem-study

Patients recruited by the GPs receive standard care during the control period. After the implementation of the MTM-approach a first comprehensive Medication Review is performed by the pharmacists as well as a support by the home-care specialists using case management techniques (see Table [1](#Tab1){ref-type="table"}). The Medication Review and the personal support by the home-care specialists are repeated after 6 months. The GP is free to accept or deny any suggestions made by the pharmacists and health-care specialists and keeps his or her unrestricted individual freedom of choice at all time during the study period. Primary and secondary endpoints are assessed at baseline and 3, 6, 9, 12 and 15 months post-baseline. Patient groups are compared with respect to their treatment response within the study period.Table 1Components of the intervention and training strategy for its implementation. This table summarizes the components of the intervention and planned training strategiesComponents of intervention and implementationContentParticipants*Intervention*I. Transfer of medical patient dataInformation concerning diagnosis, patient's medication, quality of life, mobility, risk of failing, allergiesGPII. Assessment at patients siteBrown bag review and collection of information concerning side effects, adherence, social support and elseHome-care specialist, patientIII. Anonymised data transfer to pharmacistAssessment dataHome-care specialistIV. Medication review and SOAP noteAssessment of pharmacotherapy, generation of a new medication plan, suggestions for monitoring and patient counseling2 Pharmacists per patient (one pharmacist generates a first draft of the SOAP note, second one reviews suggested plan)V. Transfer of the SOAP note to home-care specialistSOAP note and advices addressing home-care specialist tasksPharmacistVI. Information of GPSOAP note with new medication plan, home-care specialist's note for the GP (concerning for example home-care devices)Home-care specialist*Training concept for implementation*I. Kick-off meetingsInformation concerning organizational aspects, process's time frame, controlling tools, assessment instrumentsHome-care specialists, pharmacists, GPs and moderatorsII. profession-specific trainingsTraining in medication therapy management, medication review and SOAP-writingHome-care specialists, pharmacists, and moderatorsTraining in case managementIII. training in patient assessmentAssessment instruments, case studiesGPs and moderatorsIV. Process controllingOngoing feedbacks on process performance (e.g. accepted interventions, time frame)All participants

Primary hypothesis {#Sec11}
------------------

It is proposed that patients receiving the interprofessional MTM show a significantly lower MAI score compared to patients receiving standard care \[[@CR25], [@CR26]\]. Therefore the study evaluates the primary null hypothesis that an interprofessional Medication Therapy Management approach has no influence on the quality of drug therapy.

Randomization {#Sec12}
-------------

Participating clinics were randomly allocated to one of three study arms. A biometrician who is not involved in the field work, randomly selects the clinics. To avoid changes in physician's prescription behavior, random lists remain concealed until each allocation date.

Ethics and funding {#Sec13}
------------------

The study protocol was approved by the responsible local Ethics Committee in the Westphalia-Lippe region (approval number AKZ-2013-292-f-s) and will be conducted to the principles of the Declaration of Helsinki.

The study is granted by the European Union and the German State of North-Rhine-Westphalia as part of the competitive call IuK&Gender Med.NRW. Study protocol was part of the funding proposal, which was peer-reviewed by an interprofessional selection committee.

Study population {#Sec14}
----------------

### Patient recruitment {#Sec15}

The recruitment of the patients is carried out by the participating GPs. To avoid selection bias, patients' inclusion comprises of two steps. At first, all patients are screened for the defined in- and exclusion criteria. GPs systematically identify patients who are generally eligible for study inclusion. Potential study patients are listed in alphabetic order and are numbered consecutively (basic population). In a second step GPs add gender, age, and conditions (diagnoses) to this list. At a later date physicians provide a pseudonymous version of the recruitment list to the biometricians who determine a random sample of patients. These participants are informed about the study by their GP and asked to participate. After giving informed consent, baseline documentation forms and questionnaires are completed. For every patient of the sample list who declines participation, a new patient is drawn from the basic population pool. For potential study patients who decline participation a sensitivity analysis is planned at the end of the trial to determine whether this sample differs according to age, gender and structure of acute, as well as chronic conditions.

Figure [2](#Fig2){ref-type="fig"} illustrates the flowchart for recruitment of primary care units and patients.Fig. 2CONSORT flowchart of recruitment of practices and patients (projected). This figure illustrates the projected recruitment flowchart of the WestGem-study

### Inclusion and exclusion criteria {#Sec16}

The following inclusion criteria are defined:patients age ≥ 65 years,at least 3 chronic diseases out of two organ systems with one being a cardiovascular disease (for the identification of relevant chronic diseases the list published by van den Bussche et al. 2011 was used \[[@CR37]\]),at least 1 visit to the Primary Care Provider in each of the last 3 quarters,at least 5 chronic systemic available medications,(signed informed consent).

Patients with an insufficient ability to speak or read German, participation in other studies at the present time and with the existence of severe illnesses that might be lethal within 12 months according to the GP's judgment are excluded.

### Sample size and power calculation {#Sec17}

Sample size calculation for the stepped wedge design is based on Woertman et al. \[[@CR38]\]. Because there were no studies investigating the effect of Medication Management an effect size of 0.25 is considered as clinically and socially relevant. Based on this assumption and using a two-tailed *t*-test with statistical power of 80 % and significance level alpha = 0.05 a total unadjusted sample size of *N* = 502 is needed. An assumption of 20 patients per practice and little correlation between the clusters (ICC = 0.05) leads to a design factor of 0.383 in the present step wedge model. Adjusting the sample size with the design factor and considering a maximum drop-out rate of 20 % the final sample size is calculated to *N* = 240.

Data collection {#Sec18}
---------------

The main data collection comprises of paper-pencil questionnaires and documentation forms for chart reviews as well as telephone interviews with patients. After obtaining written informed consent, patients are registered in the study coordinating center of the Department of Health Care Management and Public Health Wuppertal (Germany).

Patients are asked to fill in a questionnaire. GPs document additional data from patients' chart and assess the current clinical status of the patient (e.g. blood pressure, Tinetti test, mini-mental state examination).

Patient questionnaire, chart review and telephone interview are performed at baseline (t0/t1), 3 months post-baseline (t2), 6 months (t3), 9 months post-baseline (t4), 12 months post-baseline (t5) and 15 months post-baseline (t6). The baseline documentation includes a retrospective assessment period over six month.

The pharmacists' and home-care specialists' assessment and reporting instruments are evaluated to gain the following information:medication appropriateness index (MAI) \[[@CR25], [@CR26]\];medication regimen complexity index (MRCI) \[[@CR27]\];potential inadequate medication,drug related problems,possible medical interactions,number of taken over-the-counter medication,deviation between the GPs prescribing and the brown bag,patient's therapeutic goals,experienced side effects andfurther interventions suggested during Medication Review.

Within semi-standardized and guideline-based telephone interviews GPs are interviewed twice (at the beginning and at the end of study) to discuss their expectations toward and experiences with the interprofessional Medication Therapy Management approach. To gain influencing factors on physician and study site level, a standardized questionnaire is used that was developed in a previous study \[[@CR39]\].

Outcome measures {#Sec19}
----------------

### Primary outcome {#Sec20}

The primary objective of this study is to determine whether the complex intervention can change the quality of medication therapy. Therefore specialised study pharmacists measure the quality of medication therapy at baseline (t0/t1), 3 months post-baseline (t2), 6 months (t3), 9 months post-baseline (t4), 12 months post-baseline (t5) and 15 months post-baseline (t6) by applying the MAI, a validated instrument with good intra-rater and inter-rater reliability, as well as face and content validity \[[@CR40], [@CR25], [@CR41], [@CR26]\].

The MAI is an implicit (judgment-based) process measure, which assesses ten elements of prescribing: indication, effectiveness, dose, correct directions, practical directions, drug-drug interactions, drug-disease interactions, duplication, duration and cost. To standardize the rating process, the index has operational definitions and instructions. The ratings result in a weighted score that serves as a summary measure of prescribing appropriateness \[[@CR25], [@CR26], [@CR22]\]. We assume that an increase in appropriate polypharmacy would improve indicators of morbidity such as reduction in adverse drug events (ADEs) or hospital admissions, which are both also followed in this study. Furthermore we suggest that appropriate prescribing would positively influence mortality as well as morbidity and quality of life.

The choice for the process measure MAI as primary outcome parameter was made in consideration of a current Cochrane review \[[@CR42]\] determining, which interventions are effective in improving the appropriate use of polypharmacy, reducing medication-related problems in older people and avoiding hospital admissions. The review reported that the majority of the eligible studies (seven out of eleven) used the validated MAI as a primary outcome. To determine whether the MAI can predict patient relevant outcomes and to assess its predictive validity, additional analyses are planned. More specifically, it will be examined whether any changes in the primary outcome measure result in changes in the secondary outcomes.

### Secondary outcomes {#Sec21}

Additional information regarding the quality of medication therapy will be obtained from assessment instruments used by the study pharmacists within their Medication Review. These documents includethe number of drug related problems, classified according to PCNE version 6.2,medication complexity, measured by the medication complexity index (MRCI) \[[@CR27]\],the prevalence of inadequate medication, using the PRISCUS-list \[[@CR2]\] for assessment (see Table [2](#Tab2){ref-type="table"}).Table 2Outcome parameters and instruments. This table displays the outcome parameter of the study as well as instrumentsOutcome parameterInstrumentData sourcePrimary outcomeQuality of medication therapyMedication Appropriateness Index (MAI)PHARMSecondary outcomesSociodemographic dataItems from German standard questionnaire \[[@CR47]\]CRF, TILaboratory dataPatient chartCRFDiagnosisPatient chart (ICD-10)CRFAllergiesPatient chartCRFComorbiditiesCumulative Illness Rating Scale Geriatric Version (CIRS) \[[@CR48]\]CRFReported side effectsSelf-developed itemCRF, TIQuality of LifeEuroQol (EQ-5D) \[[@CR49]\], Short Form 12 Health Questionnaire (SF-12) \[[@CR50]\]PQ, TIDepressionPatient Health Questionnaire (PHQ9) \[[@CR51]\]PQActivities of daily livingADL, iADL \[[@CR52], [@CR53]\]TIRisk of fallingTinetti-Test \[[@CR54]\]CRFMobilityFFB-Mot \[[@CR55]\]TICognitive statusAdopted Mini-Mental State Examination (MMSE)CRFPainGerman Chronic Pain Scale \[[@CR56]\]PQ, TISelf-rated healthSelf-developed itemPQVision and hearingSelf-developed itemTIHealth behavior (smoking, drinking)Self-developed itemPQ, TISocial participationF-SOZU K14 \[[@CR57]\]TIPrescribed medicationPatient chartCRFBrown bag medicationSelf-developed assessment instrumentHCSHealthcare utilization and costsData from inpatient and outpatient care, rehabilitation, medical devices, etc.CRFComplexity of medicationMedication regimen complexity index (MRCI) \[[@CR27]\]PHARMAdherenceMARS, MORISKY \[[@CR25], [@CR26]\]TIDrug-related ProblemsClassification according PCNE version 6.2PHARMInadequate medicationPotentially inadequate medication (German PRISCUS-list) \[[@CR2]\]PHARMPatients goals of therapySelf-developed assessment instrumentHCSDifficulties in medication handlingSelf-developed assessment instrumentHCSNutritionSelf-developed assessment instrumentHCSDizzinessSelf-developed assessment instrumentHCSMortalityPatient chartCRFAccepted medication proposalsSelf-developed itemCRFAdditional parametersBarriers of concept implementationQualitative research approachTI, FGPractice characteristicsSelf-developed questionnaire \[[@CR39]\]TI, on-site monitoring*PHARM* pharmacists, *HCS* home-care specialist, *PQ* patient questionnaire, *CRF* case report form, *TI* telephone interview, *FG* focus groups

Data according to over-the-counter medication, drugs prescribed by specialists, reported side effects, patients goals of therapy, patient reported medication and the risk of falling are provided by the assessment instrument of the home-care specialists.

The medication adherence is determined according to Morisky and MARS. Health related quality of life is assessed using the Short Form 12 Health Questionnaire (SF-12) and the EuroQoL instrument EQ-5D. We are documenting these instruments using a paper-based patient questionnaire as well as during the telephone interviews. Discrepancies between the two measures will be analysed.

Other secondary outcome parameters are: depression (PHQ-9), self-rated health, activities of daily living (ADL/iADL), mobility (FFB-Mot), pain (GCPS), mortality, hospital admissions, number and type of accepted medication proposals, social participation (F-SOZU K14), health care utilization and total healthcare costs.

Additionally quantitative (process documentation instruments) and qualitative (focus groups, narrative interviews) process evaluation is conducted to identify possible barriers of implementation and to detect needs to modify the intervention.

Statistical analyses {#Sec22}
--------------------

Baseline and demographic characteristics are analysed descriptively (number of valid cases, mean, standard deviation, minimum, median, lower and upper quartile, maximum for quantitative variables and number and proportions for qualitative variables).

The statistical analyses of the full-analysis set will follow the intention-to-treat (ITT) principle. This dataset includes all trial subjects who are randomized, meet all inclusion and exclusion criteria, have signed informed consent and have at least a baseline MAI score. Supportive analyses will be performed for the per-protocol (PP) population that includes all trial subjects of the ITT set who were treated as randomized and have at least two MAI scores after changing from control to intervention.

The primary hypothesis will be evaluated by a mixed model with treatment group and time as fixed effects and clustering structure as random effect. Significance level is set to alpha = 5 % (two-sided). It is assumed that values are missing at random (MAR) therefore no values need to be replaced in the mixed model. Secondary outcomes are analysed analogously. Further analyses are performed exploratory. In the sensitivity analysis missing values are replaced with last observation carried forward (LOCF).

Subgroup analyses will be performed with respect to age, gender, migrant status, social bonding and complexity of morbidity structure.

### Cost-effectiveness {#Sec23}

The cost-effectiveness analysis is performed from a societal perspective. Therefore direct costs are calculated. We will exclude indirect costs as we assume that these are not relevant for our included patient group. To calculate the documented resource utilization we use administrative and market prices.

As effect measure QALYs are calculated from the EQ-5D and as the point estimate the incremental costs per QALY will be determined.

To take uncertainty into account a cost-effectiveness-acceptability-curve is computed, using non-parametric bootstrapping methods. Furthermore, a net-monetary benefit regression analysis will be performed \[[@CR43]\].

Methods against bias and for quality assurance {#Sec24}
----------------------------------------------

To ensure data quality and to avoid missing data or processes which are not adherent with the study protocol, clinical research associates visit study sites for clinical monitoring. Furthermore several routines, like a data handling report, are established to prevent or detect incorrect as well as inconsistent data entry and incomplete data. In this regard a random sample of paper-pencil questionnaires is compared with the data entries in the database. Additionally, regular training sessions are done.

Intervention {#Sec25}
------------

### Interprofessional Medication Therapy Management approach {#Sec26}

Pharmacists perform a comprehensive Medication Review (PCNE type 3). They receive the patient data from the GP and from the home-care specialists (see Table [1](#Tab1){ref-type="table"}). All data reaching the pharmacists is anonymised. Besides their own assessments, home-care specialists perform several assessments at the patients' site for the pharmacists. At these visits a "brown bag review" of the drugs in use by the patient is performed as well as an intense patient interview, covering a list with all the questions a pharmacist would ask a patient including side effects, difficulties in handling, adherence, nutrition, dizziness, social support and else. The home-care specialists furthermore evaluate the demand of the patient for home-care devices or products, social and financial support and identify tripping hazards and potential risks. The pharmacists transfer all the provided data to a calculation sheet for statistical purposes and develop a message to the GP based on the SOAP-note form.

In a first attempt, the data of the brown bag review is compared to the medication plan of the GP. Deviations are registered and possible explanations are assumed and added. Based on the diagnoses, the laboratory data and the reported complaints, individual therapeutic goals are generated and the glomerular filtration rate (GFR) is calculated using the Cockroft-Gault equation. The pharmacotherapy is assessed on:drug-drug interactions,contraindications,suitability to reach the therapeutic goals,guideline accordance,difficulties in handling the drugs,problems of timing and drug-food interactions,indications without a drug,drugs without an indication,duplications,toxicity/dose/geriatric appropriateness,drug monitoring,appropriateness of lengths of therapy,side effects andcosts.

Depending on the patient further problems are assessed. Pharmacists are discussing favourable interventions and are generating a new medication plan. Suggestions for monitoring parameters and patient counseling are expressed. A SOAP note to the GP is written. Estimations on the disease related and drug depending falling risk are provided to the home-care specialists.

### Intervention for the control group {#Sec27}

At control condition patients receive standard treatment by their GP and other health care providers within the regular German health care system.

Discussion {#Sec28}
==========

Interprofessional Medication Therapy Management for multimorbid patients receiving polypharmacy may improve quality of medication therapy and outcomes. MTMs have increasingly been recognized as a resource in overcoming shortages in primary care \[[@CR44]\].

The study investigates a new type of collaboration between GPs, pharmacists and home-care specialists in outpatient care and combines case management routines of the home-care specialists at the patient-site with information gained during the advanced Medication Review by specialised and clinical experienced study pharmacists.

The emphasis on interprofessional cooperation and collaboration with the participation of physicians, pharmacists and home-care specialists has a greater potential to show an improvement in the interventions compared to drug safety and therapy management programs by a single profession alone. It is strongly believed that the future of optimising a patient's therapy as well as reducing patient's drug risks can only be provided by a collaborative health care team consisting of different professions. In this trial the home-care specialists provide their patient oriented insight to the pharmacists and physicians. They suggest interventions relating to patient care directly to the GPs. Pharmacists perform the Medication Review not only with a focus on drug safety but also on the quality of therapy, therapeutic outcomes and patient goals. The GPs outweigh all these suggestions, perform several assessments with the patient and are free to choose the best therapeutic alternatives, based on their own judgment.

The patient interview and brown bag review are activities, typically provided by the pharmacist \[[@CR45], [@CR46]\]. All investigations at the patient are performed by the physician and the home-care specialists, according to a standardized and comprehensive list. The pharmacists are referred to as research pharmacists at a different location who receive only anonymised data. The reasons for this blinded approach are various. In a regional setting patients do not want to see an unknown pharmacist to receive all their data. There might be strong relations of the patients toward a different pharmacy. Personal relations and social ties to a pharmacist are very important for elderly patients in Germany. There might be a strong skepticism of the patient toward foreign pharmacies and pharmacists, which might be a major barrier and confounder in a regional and community setting. As a MTM is unknown to most participating GPs, they might as well hesitate to share their data with a local pharmacist as they feel controlled by them at this stage. At introductory interviews patients and physicians clearly preferred to stay anonymous. As pharmacists in this trial do not need a personal meeting with the patients at the site, a strength of being anonymous is that highly trained pharmacotherapy experts from different areas in Germany can enter the team. The considered study-pharmacists need to be specialists in clinical pharmacy and pharmacotherapy with additional clinical education, experience and training. For participation in this complex study therapeutic knowledge and scientific experience is indispensable. Handling of the MAI needs further training and skills to meet research standards. Based on these criteria a nationwide team of pharmaceutical researchers is recruited to build the team of MTM-experts. A weakness of being anonymous is that some patient related data might reach the pharmacists in a way, which might differ from self-acquired data.

Trial status {#Sec29}
============

Pilot testing of study documents and site recruitment were conducted in March--August 2013. Patient recruitment and baseline data collection were conducted in September--December 2013. The interprofessional medication therapy management intervention was delivered in January 2014--March 2015. Outcome data were collected in January 2014--March 2015. At the time of submission of the manuscript, data cleaning and analysis has just started.
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